← Back to Mandates

Novera Diagnostics

Healthcare · Boston MA · Active Mandate
Deal Size
$42M
Revenue
$31M
Growth
33%
EBITDA Margin
24%
Ready Now
Sellability Score
84/100
Asset quality, growth, margins
Buyer Readiness
79/100
Buyer universe engagement
Momentum Score
71/100
Process activity and recency
Intelligence Summary
Strong diagnostics IP and good revenue growth. Healthcare-focused PE firms are actively interested. Momentum is building — close attention warranted.
Owner Intelligence Profile
OP
Owner Profile
Founder · ·
Succession Risk
Unknown
Communication Style
Profile pending — complete discovery call to populate.
Motivation Profile
Profile pending.
Succession Intelligence
Detailed owner intelligence not yet available for this mandate. Schedule discovery call to build profile.
Live Signals
Intelligence scan pending
Situational Triggers
Run intelligence scan to surface situational triggers
Trust-Building Tactics
+
Complete owner discovery to generate trust triggers
Avoid
—
Complete owner discovery to generate avoid list
Recommended First Outreach Script
"Complete owner profile to generate personalized outreach script."
Recommended Follow-Up Script
"Complete owner profile to generate follow-up script."
Historical Pattern Match
Pattern Match
Insufficient data
Est. Time to Close
Unknown
Key Risk
Complete intelligence scan to identify k...
Upload historical deal data during onboarding to enable pattern matching.
Recommended Buyers
Linden CapitalPE
Linden healthcare PE, diagnostics strong fit
93
Welsh CarsonPE
Welsh Carson healthcare and tech focus
88
Stryker CorpStrategic
Stryker exploring diagnostics adjacency
79
Recent Interactions
Linden Capitalloi2024-11-11
Linden Capital submitted IOI. First formal indication.
Gryphon Investorsnda signed2024-11-09
NDA signed, CIM under review.
Linden Capitalnda signed2024-11-06
IP reviewed, strong interest.
Welsh Carsonmanagement meeting2024-11-04
Met with R&D team. Very positive.
Gryphon Investorsintro call2024-10-30
In initial review.
Riverside Companyintro call2024-10-25
Riverside initial interest in diagnostics.
Stryker Corpintro call2024-10-20
Stryker exploring diagnostics adjacency.